YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that it has filed an amendment with the FDA to its existing IND to expand the use of its product, AVR118 to include topical and intralesional therapy. These applications could potentially be used to treat a wide variety of common dermatologic conditions that are extremely problematic to treat.
